Stock LUMO LUMOS PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Lumos Pharma, Inc.

Equities

LUMO

US55028X1090

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
3.04 USD +0.66% Intraday chart for Lumos Pharma, Inc. +10.14% -4.40%
Mar. 07 Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 07 Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024

Evolution of the average Target Price on Lumos Pharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

2a5fa71be8cb26a.rmpGr47mBPa1zcjWIMZNpKpgWIX74ByazaBHVTaeQiw._Fwn7tieR8DstIasa-sYzs8tFMKJhG3Qv8k3Zkb2EkLLBwP86rddlP-FhQ~e893d7c3472721beecc46837daa283e5

Analyst Recommendations on Lumos Pharma, Inc.

Oppenheimer Trims Lumos Pharma Price Target to $16 From $17, Maintains Outperform Rating MT
Cantor Fitzgerald Adjusts Lumos Pharma's Price Target to $10 From $14, Keeps Overweight Rating MT
Oppenheimer Adjusts Lumos Pharma Price Target to $17 From $18, Maintains Outperform Rating MT
Jefferies Downgrades Lumos Pharma to Hold From Buy, Adjusts Price Target to $7 From $17 MT
Jefferies Downgrades Lumos Pharma to Hold From Buy With $7 Price Target MT
Oppenheimer Initiates Coverage on Lumos Pharma With Outperform Rating, $20 Price Target MT
LUMOS PHARMA : Roth Capital Adjusts Lumos Pharma's Price Target to $35 From $51, Maintains Buy Rating MT
Lumas Pharma Shares Drop 12% After Treatment Period Extended DJ
LUMOS PHARMA : HC Wainwright Adjusts Price Target on Lumos Pharma to $27 From $34, Maintains Buy Rating MT
LUMOS PHARMA : JonesTrading Starts Lumos Pharma at Buy with $34 Price Target MT
LUMOS PHARMA : Stifel Upgrades Lumos Pharma to Buy From Hold, Adjusts Price Target to $24 From $4 MT
LUMOS PHARMA : Cantor Fitzgerald Starts Lumos Pharma at Overweight with $32 Price Target MT
LUMOS PHARMA : HC Wainwright Adjusts Lumos Pharma's Price Target to $34 From $33, Reiterates Buy Rating MT
NewLink Genetics Corporation Announces Interim Phase 2 Data Demonstrate Robust Response Rate with Indoximod CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.04 USD
Average target price
22.5 USD
Spread / Average Target
+640.13%
High Price Target
28 USD
Spread / Highest target
+821.05%
Low Price Target
16 USD
Spread / Lowest Target
+426.32%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Lumos Pharma, Inc.

Oppenheimer
Cantor Fitzgerald
Jefferies & Co.
Roth Capital Partners
HC Wainwright
JonesTrading Institutional Services
Stifel Nicolaus

Ratings for Lumos Pharma, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LUMO Stock
  4. Consensus Lumos Pharma, Inc.